NCT06285422View on ClinicalTrials.gov

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2029

Conditions
Non Hodgkin's LymphomaLarge B-cell Lymphoma
Interventions
DRUG

SC262

SC262 is an allogeneic CAR -T cell therapy

Trial Locations (3)

66160

RECRUITING

The University of Kansas Hospital, Kansas City

98104

RECRUITING

Swedish Cancer Institute, Seattle

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

Sponsors

Lead Sponsor

Sana Biotechnology
All Listed Sponsors
lead

Sana Biotechnology

INDUSTRY

NCT06285422 - Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) | Biotech Hunter | Biotech Hunter